A Phase I/IIa Randomized Trial Evaluating the Safety and Efficacy of SNK01 Plus Pembrolizumab in Patients with Stage IV Non-Small Cell Lung Cancer
CONCLUSION: Based on the findings of this study, the NK cell combination therapy may consider as a safe treatment method for stage IV NSCLC patients who had a history of failed platinum-based therapy without an increase in adverse events (AEs).PMID:34856706 | DOI:10.4143/crt.2021.986
Source: Cell Research - Category: Cytology Authors: Eo Jin Kim Yong-Hee Cho Dong Ha Kim Dae-Hyun Ko Eun-Ju Do Sang-Yeob Kim Yong Man Kim Jae Seob Jung Yoonmi Kang Wonjun Ji Myeong Geun Choi Jae Cheol Lee Jin Kyung Rho Chang Min Choi Source Type: research
More News: Cancer | Cancer & Oncology | Clinical Trials | Cytology | Lung Cancer | Non-Small Cell Lung Cancer | Study | Toxicology